PE20090441A1 - DERIVADOS DE IMIDAZO[1,2-a]PIRIDIN-2-ILMETIL PIPERIDINA SUSTITUIDA - Google Patents

DERIVADOS DE IMIDAZO[1,2-a]PIRIDIN-2-ILMETIL PIPERIDINA SUSTITUIDA

Info

Publication number
PE20090441A1
PE20090441A1 PE2008001119A PE2008001119A PE20090441A1 PE 20090441 A1 PE20090441 A1 PE 20090441A1 PE 2008001119 A PE2008001119 A PE 2008001119A PE 2008001119 A PE2008001119 A PE 2008001119A PE 20090441 A1 PE20090441 A1 PE 20090441A1
Authority
PE
Peru
Prior art keywords
alkyl
imidazo
methyl
pyridin
alcoxy
Prior art date
Application number
PE2008001119A
Other languages
English (en)
Inventor
Giuseppe Alvaro
David Amantini
Sandro Belvedere
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0712887A external-priority patent/GB0712887D0/en
Priority claimed from GB0804317A external-priority patent/GB0804317D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20090441A1 publication Critical patent/PE20090441A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE IMIDAZO[1,2-a]PIRIDIN-2-ILMETIL PIPERIDINA SUSTITUIDA DE FORMULA (I) DONDE Ar ES UN COMPUESTO DE FORMULA (II) O (III); R1 ES ALQUILO(C1-C4), HALOGENO, HALOALQUILO(C1-C4), ALCOXI(C1-C4), ENTRE OTROS; R2 ES ALQUILO(C1-C4), ALQUENILO(C2-C4), CN, NR7R8, ENTRE OTROS, DONDE R7 Y R8 SON CADA UNO H O ALQUILO(C1-C4); R3 ES ALQUILO(C1-C4), ALCOXI(C1-C4), CN, NR9R10, ENTRE OTROS, DONDE R9 Y R10 SON CADA UNO H O ALQUILO(C1-C4); R4 ES ALQUILO(C1-C4), HALOGENO, HALOALQUILO(C1-C4), ALCOXI(C1-C4), ENTRE OTROS; n, p, q Y r SON CADA UNO 0 O 1. SON COMPUESTOS PREFERIDOS: 2-[((2S)-1-{[5-(4-FLUOROFENIL)-2-METIL-1,3-TIAZOL-4-IL]CARBONIL}-2-PIPERIDINIL)METIL]-7-(TRIFLUOROMETIL)IMIDAZO[1,2-a]PIRIDINA, 2-({(2S)-1-[(2-METIL-5-FENIL-1,3-TIAZOL-4-IL)CARBONIL]-2-PIPERIDINIL}METIL)-7-(TRIFLUOROMETIL)IMIDAZO[1,2-a]PIRIDINA, 2-({(2S)-1-[(2-METIL-5-FENIL-1,3-TIAZOL-4-IL)CARBONIL]-2-PIPERIDINIL}METIL)-6-(TRIFLUOROMETIL)IMIDAZO[1,2-a]PIRIDINA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS DE UN RECEPTOR DE OXERINA HUMANO SIENDO UTILES EN EL TRATAMIENTO DE OBESIDAD, INSOMNIO PRIMARIO, HIPERSOMNIO PRIMARIO, NARCOLEPSIA
PE2008001119A 2007-07-03 2008-07-01 DERIVADOS DE IMIDAZO[1,2-a]PIRIDIN-2-ILMETIL PIPERIDINA SUSTITUIDA PE20090441A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0712887A GB0712887D0 (en) 2007-07-03 2007-07-03 Novel compounds
GB0804317A GB0804317D0 (en) 2008-03-07 2008-03-07 Novel compounds

Publications (1)

Publication Number Publication Date
PE20090441A1 true PE20090441A1 (es) 2009-05-08

Family

ID=39789338

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001119A PE20090441A1 (es) 2007-07-03 2008-07-01 DERIVADOS DE IMIDAZO[1,2-a]PIRIDIN-2-ILMETIL PIPERIDINA SUSTITUIDA

Country Status (18)

Country Link
US (2) US20120095034A1 (es)
EP (1) EP2176258A1 (es)
JP (1) JP2010531848A (es)
KR (1) KR20100030635A (es)
CN (1) CN101796053A (es)
AR (1) AR067396A1 (es)
AU (1) AU2008270294A1 (es)
BR (1) BRPI0812981A2 (es)
CA (1) CA2691638A1 (es)
CL (1) CL2008001951A1 (es)
CO (1) CO6270320A2 (es)
DO (1) DOP2009000293A (es)
EA (1) EA201070091A1 (es)
IL (1) IL202665A0 (es)
MA (1) MA31470B1 (es)
PE (1) PE20090441A1 (es)
TW (1) TW200911242A (es)
WO (1) WO2009003993A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010534647A (ja) * 2007-07-27 2010-11-11 アクテリオン ファーマシューティカルズ リミテッド ２−アザ−ビシクロ［３．３．０］オクタン誘導体
WO2009040730A2 (en) * 2007-09-24 2009-04-02 Actelion Pharmaceuticals Ltd Pyrrolidines and piperidines as orexin receptor antagonists
AU2009215243A1 (en) * 2008-02-21 2009-08-27 Actelion Pharmaceuticals Ltd. 2-aza-bicyclo[2.2.1]heptane derivatives
EP2318367B1 (en) * 2008-04-30 2013-03-20 Actelion Pharmaceuticals Ltd. Piperidine and pyrrolidine compounds
US8129384B2 (en) 2008-10-09 2012-03-06 Glaxo Group Limited Imidazo[1,2-a]pyrazines as orexin receptor antagonists
US8093255B2 (en) 2008-10-09 2012-01-10 Glaxo Group Limited Imidazo[1,2-A]pyrimidines as orexin receptor antagonists
WO2010060470A1 (en) * 2008-11-26 2010-06-03 Glaxo Group Limited Piperidine derivatives useful as orexin receptor antagonists
JP2012509911A (ja) * 2008-11-26 2012-04-26 グラクソ グループ リミテッド 新規の化合物
JP2012509912A (ja) * 2008-11-26 2012-04-26 グラクソ グループ リミテッド 新規の化合物
TW201031407A (en) 2008-12-02 2010-09-01 Glaxo Group Ltd Novel compounds
GB0823467D0 (en) 2008-12-23 2009-01-28 Glaxo Group Ltd Novel Compounds
CN102459229A (zh) 2009-04-24 2012-05-16 葛兰素集团有限公司 用作食欲肽拮抗剂的3-氮杂二环[4.1.0]庚烷
DK2491038T3 (da) 2009-10-23 2016-07-18 Janssen Pharmaceutica Nv Disubstituerede octahydropyrrolo [3,4-c]pyrroler som orexin receptormodulatorer
US8742106B2 (en) 2009-12-21 2014-06-03 Novartis Ag Disubstituted heteroaryl-fused pyridines
WO2011138266A1 (en) * 2010-05-03 2011-11-10 Evotec Ag Indolizine and imidazopyridine derivatives as orexin receptor antagonists
JP5847830B2 (ja) * 2010-11-10 2016-01-27 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ オレキシン受容体拮抗薬として有用なラクタム誘導体
WO2012089606A1 (en) 2010-12-28 2012-07-05 Glaxo Group Limited Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists
WO2012089607A1 (en) 2010-12-28 2012-07-05 Glaxo Group Limited Novel compounds with a 3a-azabicyclo [4.1.0] heptane core acting on orexin receptors
GB201101678D0 (en) 2011-02-01 2011-03-16 Rolls Royce Plc A cooling arrangement for a magnetic gearbox
NZ703448A (en) 2012-06-04 2017-07-28 Actelion Pharmaceuticals Ltd Benzimidazole-proline derivatives
CN104703980B (zh) 2012-10-10 2017-09-22 埃科特莱茵药品有限公司 属于[邻双(杂)芳基]‑[2‑(间双(杂)芳基)吡咯烷‑1‑基]甲酮衍生物的食欲素受体拮抗剂
EP2970241A1 (en) 2013-03-12 2016-01-20 Actelion Pharmaceuticals Ltd. Azetidine amide derivatives as orexin receptor antagonists
GB201318222D0 (en) * 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
UA119151C2 (uk) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
CA2929423C (en) 2013-12-03 2021-12-07 Actelion Pharmaceuticals Ltd Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1 ,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists
AU2014358766B2 (en) 2013-12-04 2019-01-17 Idorsia Pharmaceuticals Ltd Use of benzimidazole-proline derivatives
TW201613864A (en) * 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
US10370380B2 (en) 2015-11-23 2019-08-06 Sunshine Lake Pharma Co., Ltd. Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof
CA3016706A1 (en) 2016-03-10 2017-09-14 Janssen Pharmaceutica Nv Methods of treating depression using orexin-2 receptor antagonists
WO2017194548A1 (en) 2016-05-10 2017-11-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases
WO2020007964A1 (en) 2018-07-05 2020-01-09 Idorsia Pharmaceuticals Ltd 2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives
WO2020099511A1 (en) 2018-11-14 2020-05-22 Idorsia Pharmaceuticals Ltd Benzimidazole-2-methyl-morpholine derivatives
AR129309A1 (es) 2022-05-13 2024-08-07 Idorsia Pharmaceuticals Ltd Derivados de hidrazina-n-carboxamida cíclica sustituida con tiazoloaril-metilo

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1399441B1 (en) * 2001-06-28 2006-07-05 Smithkline Beecham Plc N-aroyl cyclic amine derivatives as orexin receptor antagonists

Also Published As

Publication number Publication date
MA31470B1 (fr) 2010-06-01
EP2176258A1 (en) 2010-04-21
CO6270320A2 (es) 2011-04-20
WO2009003993A1 (en) 2009-01-08
IL202665A0 (en) 2010-06-30
JP2010531848A (ja) 2010-09-30
KR20100030635A (ko) 2010-03-18
US20120095034A1 (en) 2012-04-19
AR067396A1 (es) 2009-10-07
DOP2009000293A (es) 2010-03-31
CA2691638A1 (en) 2009-01-08
AU2008270294A1 (en) 2009-01-08
CL2008001951A1 (es) 2009-01-09
EA201070091A1 (ru) 2010-06-30
US20090022670A1 (en) 2009-01-22
CN101796053A (zh) 2010-08-04
TW200911242A (en) 2009-03-16
BRPI0812981A2 (pt) 2014-12-16

Similar Documents

Publication Publication Date Title
PE20090441A1 (es) DERIVADOS DE IMIDAZO[1,2-a]PIRIDIN-2-ILMETIL PIPERIDINA SUSTITUIDA
PE20080557A1 (es) Compuestos de azabencimidazolilo con actividad sobre los receptores glutamato
AR049696A1 (es) Derivados de indol
ECSP045368A (es) "antagonistas de los receptores de trombina"
ATE466842T1 (de) 3-substituierte pyridinderivate als h3- antagonisten
PE20091353A1 (es) Nuevos compuestos heterociclicos
PE20090816A1 (es) Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
PE20091818A1 (es) DERIVADOS POLISUSTITUIDOS DE 2-ARIL-6-FENIL-IMIDAZO[1,2-a] PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
PE20130012A1 (es) Derivados de pirazol como inhibidores de jak
PE20061297A1 (es) Compuestos derivados de cromano y cromeno moduladores del receptor de serotonina 5-ht2c
PE20091819A1 (es) DERIVADOS POLISUSTITUIDOS DE 2-HETEROARIL-6-FENIL-IMIDAZO[1,2-a] PIRIDINAS, SU PREPARACION Y SU APLIACION EN TERAPEUTICA
AR056445A1 (es) Derivados arilicos y heteroarilicos de 6 miembros para tratar virus
AR044499A1 (es) Pirimidinas sustituidas con indano inhibidoras de la replicacion del hiv
PE20120593A1 (es) Derivados fusionados de pirimidin-4-ona como antagonistas del receptor de angiotensina ii y como agonistas del receptor ppar gamma
MY139058A (en) Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
PE20061378A1 (es) INHIBIDORES DE LA ACTIVIDAD DE Akt
UY29204A1 (es) Compuestos de imidazo(1,2-a)piridina, composiciones, usos y métodos relacionados
PE20110405A1 (es) Derivados de piridino-piridinonas como inhibidores de la actividad de la tirosina quinasa de pdgf-r y/o flt-3 y su preparacion
PE20070212A1 (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
PE20070069A1 (es) Piperazin-piperidinas como antagonistas y agonistas del receptor 5-ht1a
AR056883A1 (es) Derivados de 7-azaindol-2 carboxamida, un proceso para la preparacion de los mismos, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades asociadas con la modulacion de receptores de h3
BRPI0519709A2 (pt) derivados de tetralina e indano e usos dos mesmos como antagonistas de 5-ht
PE20081665A1 (es) Antagonistas del receptor de dopamina 2 de rapida disociacion
TW200606153A (en) Process for producing pyridine derivatives of Nk-1 receptor antagonist

Legal Events

Date Code Title Description
FC Refusal